Page 121 - 《中国药房》2025年8期
P. 121

[ 2 ]  中国医师协会神经内科医师分会疼痛和感觉障碍专委                          Rev,2019,1(1):CD007076.
              会. 糖尿病性周围神经病理性疼痛诊疗专家共识[J]. 中                   [15]  LIAN J X,MA L T,FU J F. Different drugs for the treat‐
              国疼痛医学杂志,2018,24(8):561-567.                         ment  of  painful  diabetic  peripheral  neuropathy:a  meta-
          [ 3 ]  LI C X,WANG W M,JI Q H,et al. Prevalence of painful   analysis[J]. Front Neurol,2021,12:682244.
              diabetic peripheral neuropathy in type 2 diabetes mellitus   [16]  WIFFEN P J,DERRY S,BELL R F,et al. Gabapentin for
              and  diabetic  peripheral  neuropathy:a  nationwide  cross-  chronic neuropathic pain in adults[J]. Cochrane Database
              sectional  study  in  mainland  China[J].  Diabetes  Res  Clin   Syst Rev,2017,6(6):CD007938.
              Pract,2023,198:110602.                         [17]  ZHANG  S  S,WU  Z,ZHANG  L  C,et  al.  Efficacy  and
          [ 4 ]  ZHANG Y J,ZHANG S W,PAN L Y,et al. Painful dia‐  safety of pregabalin for treating painful diabetic peripheral
              betic  peripheral  neuropathy  study  of  Chinese  outpatients  neuropathy:a meta-analysis[J]. Acta Anaesthesiol Scand,
              (PDNSCOPE):a  multicentre  cross-sectional  registry   2015,59(2):147-159.
              study of clinical characteristics and treatment in mainland   [18]  杨丽娟,林平,梁健华,等. 普瑞巴林治疗糖尿病性周围
              China [J]. Pain Ther,2021,10(2):1355-1373.          神经痛的治疗效果与安全性的 Meta 分析[J]. 中国药学
          [ 5 ]  高胜男,张冉冉,张羽曦,等. 我国糖尿病神经病理性疼                       杂志,2013,48(21):1881-1885.
              痛疾病负担及药物治疗进展[J]. 临床荟萃,2024,39(9):              [19]  BELLOWS  B  K,DAHAL  A,JIAO  T  Z,et  al.  A  cost-
              842-846.                                            utility  analysis  of  pregabalin  versus  duloxetine  for  the
          [ 6 ]  叶冬炜,王莉,刘叔文. 卫生技术评估在欧洲4国的应用                       treatment of painful diabetic neuropathy[J]. J Pain Palliat
                                                                  Care Pharmacother,2012,26(2):153-164.
              及对我国的启示[J]. 中国药房,2022,33(1):1-6.
                                                             [20]  BELLOWS  B  K,NELSON  R  E,ODERDA  G  M,et  al.
          [ 7 ]  HAILEY  D.  Toward  transparency  in  health  technology
                                                                  Long-term  cost-effectiveness  of  initiating  treatment  for
              assessment:a checklist for HTA reports[J]. Int J Technol
                                                                  painful  diabetic  neuropathy  with  pregabalin,duloxetine,
              Assess Health Care,2003,19(1):1-7.
                                                                  gabapentin,or desipramine[J]. Pain,2016,157(1):203-213.
          [ 8 ]  张方圆,沈傲梅,曾宪涛,等. 系统评价方法学质量评价
                                                             [21]  CARLOS  F,RAMÍREZ-GÁMEZ  J,DUEÑAS  H,et  al.
              工具 AMSTAR 2 解读[J]. 中国循证心血管医学杂志,
                                                                  Economic  evaluation  of  duloxetine  as  a  first-line  treat‐
              2018,10(1):14-18.
                                                                  ment for painful diabetic peripheral neuropathy in Mexico
          [ 9 ]  HUSEREAU  D,DRUMMOND  M,AUGUSTOVSKI  F,
                                                                  [J]. J Med Econ,2012,15(2):233-244.
              et  al.  Consolidated  health  economic  evaluation  reporting
                                                             [22]  CARLOS F,ESPEJEL L,NOVICK D,et al. Duloxetine
              standards 2022(CHEERS 2022)statement:updated repor-
                                                                  for the treatment of painful diabetic peripheral neuropathy
              ting  guidance  for  health  economic  evaluations[J].  Value
                                                                  in Venezuela:economic evaluation[J]. Medwave,2015,15
              Health,2022,25(1):3-9.
                                                                 (8):e6265.
          [10]  刘旭婷,高胜男,齐冉,等. 异麦芽糖酐铁治疗缺铁性贫
                                                             [23]  GRAY E,YE X,WANG Y F,et al. Cost-effectiveness of
              血的快速卫生技术评估[J]. 中国药房,2022,33(24):
                                                                  mirogabalin for the treatment of diabetic peripheral neuro‐
              3040-3044.
                                                                  pathic pain in Taiwan [J]. Value Health Reg Issues,2021,
          [11]  DY SM,BENNETT WL,SHARMA R,et al. Preventing
                                                                  24:148-156.
              complications  and  treating  symptoms  of  diabetic  peri-
                                                             [24]  O’CONNOR A B,NOYES K,HOLLOWAY R G. A cost-
              pheral  neuropathy[R].  Rockville (MD) :Agency  for
                                                                  utility comparison of four first-line medications in painful
              Healthcare Research and Quality(US),2017.
                                                                  diabetic  neuropathy[J].  Pharmacoeconomics,2008,26
          [12]  ALYOUBI R A,ALSHAREEF A A,ALDUGHAITHER S
                                                                 (12):1045-1064.
              M,et al. Efficacy and safety of mirogabalin treatment in   [25]  ROY  M  K,KURIAKOSE  A  S,VARMA  S  K,et  al.  A
              patients  with  diabetic  peripheral  neuropathic  pain:a  sys‐
                                                                  study  on  comparative  efficacy  and  cost  effectiveness  of
              tematic  review  and  meta-analysis  of  randomised  con‐  pregabalin  and  duloxetine  used  in  diabetic  neuropathic
              trolled trials[J]. Int J Clin Pract,2021,75(5):e13744.  pain[J]. Diabetes Metab Syndr,2017,11(1):31-35.
          [13]  ASRAR M M,KUMARI S,SEKHAR B C,et al. Relative   [26]  TARRIDE J E,GORDON A,VERA-LLONCH M,et al.
              efficacy  and  safety  of  pharmacotherapeutic  interventions   Cost-effectiveness  of  pregabalin  for  the  management  of
              for  diabetic  peripheral  neuropathy:a  systematic  review   neuropathic pain associated with diabetic peripheral neu‐
              and  Bayesian  network  meta-analysis[J].  Pain  Physician,  ropathy and postherpetic neuralgia:a Canadian perspective
              2021,24(1):E1-E14.                                  [J]. Clin Ther,2006,28(11):1922-1934.
          [14]  DERRY S,BELL R F,STRAUBE S,et al. Pregabalin for            (收稿日期:2024-09-20  修回日期:2025-01-22)
              neuropathic  pain  in  adults[J].  Cochrane  Database  Syst                         (编辑:李 劲)


          中国药房  2025年第36卷第8期                                                China Pharmacy  2025 Vol. 36  No. 8    · 1007 ·
   116   117   118   119   120   121   122   123   124   125   126